Methylglyoxal modulates immune responses: Relevance to diabetes

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1806-1815

  Price, Claire L ^a   Hassi, Hafid O S Al ^a   English, Nicholas R ^a   Blakemore, Alexandra I F ^a   Stagg, Andrew J ^b   Knight, Stella C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Advanced glycation; Dendritic cells; Diabetes; Methylglyoxal; T cells

Indexed keywords

CD83 ANTIGEN; CYTOKINE; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MESSENGER RNA; METHYLGLYOXAL;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; BONE MARROW CELL; CELL PROLIFERATION; CYTOLOGY; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; T LYMPHOCYTE;

ANTIGENS, CD; APOPTOSIS; CELL PROLIFERATION; CYTOKINES; DIABETES MELLITUS; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULINS; IMMUNOMODULATION; MEMBRANE GLYCOPROTEINS; MYELOID CELLS; PYRUVALDEHYDE; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 77955158485     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00803.x     Document Type: Article

References (29)

1. Thornalley PJ. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems-role in ageing and disease. Drug Metabol Drug Interact. 2008, 23:125-50.
2. Kalapos MP. The tandem of free radicals and methylglyoxal. Chem Biol Interact. 2008, 171:251-71.
3. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001, 108:949-55.
4. Muller LM, Gorter KJ, Hak E. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005, 41:281-8.
5. Pozzilli P, Leslie RD. Infections and diabetes: mechanisms and prospects for prevention. Diabet Med. 1994, 11:935-41.
6. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991, 9:271-96.
7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998, 392:245-52.
8. Cutler CW, Jotwani R, Pulendran B. Dendritic cells: immune saviors or Achilles' heel. Infect Immun. 2001, 69:4703-8.
9. Price CL, Sharp PS, North ME. Advanced glycation end products modulate the maturation and function of peripheral blood dendritic cells. Diabetes. 2004, 53:1452-8.
10. Lo TW, Westwood ME, McLellan AC. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem. 1994, 269:32299-305.
11. Maldonado-Lopez R, De Smedt T, Michel P. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med. 1999, 189:587-92.
12. Rissoan MC, Soumelis V, Kadowaki N. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999, 283:1183-6.
13. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev. 2008, 224:70-84.
14. McLellan AC, Thornalley PJ, Benn J, Sonksen PH. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond). 1994, 87:21-9.
15. Beisswenger PJ, Howell SK, Touchette AD. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 1999, 48:198-202.
16. Chaplen FW, Fahl WE, Cameron DC. Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 1998, 95:5533-8.
17. Fujimoto Y, Tedder TF. CD83: a regulatory molecule of the immune system with great potential for therapeutic application. J Med Dent Sci. 2006, 53:85-91.
18. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008, 180:5771-7.
19. Lohmann T, Laue S, Nietzschmann U. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes. 2002, 51:2474-80.
20. Sakowicz-Burkiewicz M, Kocbuch K, Grden M. Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes. Immunology. 2006, 118:402-12.
21. Avanzini MA, Ciardelli L, Lenta E. IFN-gamma low production capacity in type 1 diabetes mellitus patients at onset of disease. Exp Clin Endocrinol Diabetes. 2005, 113:313-7.
22. Kukreja A, Cost G, Marker J. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002, 109:131-40.
23. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies. Scand J Immunol. 2001, 53:510-3.
24. Price CL, Knight SC. Advanced glycation: a novel outlook on atherosclerosis. Curr Pharm Des. 2007, 13:3681-7.
25. Bidmon C, Frischmann M, Pischetsrieder M. Analysis of DNA-bound advanced glycation end-products by LC and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007, 853:51-8.
26. Rabbani N, Thornalley PJ. The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann N Y Acad Sci. 2008, 1126:124-7.
27. Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem. 1986, 261:13542-5.
28. Gallet X, Charloteaux B, Thomas A, Brasseur R. A fast method to predict protein interaction sites from sequences. J Mol Biol. 2000, 302:917-26.
29. Zeng J, Dunlop RA, Rodgers KJ, Davies MJ. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem J. 2006, 398:197-206.